HPV16-Positive Oropharyngeal Cancer
Embracing The Challenge To Redefine The Impossible
Next-generation therapies in oncology have shown immense promise in pre-clinical research. To translate this discovery into treatment, Revive Research Institute is involved in numerous oncology clinical trials.
Oropharyngeal cancers such as squamous cell carcinoma are the 6th most common malignancies. Studies show that HPV16-associated cancers require more aggressive treatment and often have a poor prognosis.
Revive Research Institute is conducting a study to find improved therapeutic approaches in treating HPV-associated oropharyngeal cancers.
We aim to transform the landscape of future oncology medicine. Join us in our studies and help find treatments that can improve quality of life.
- Be 18 years of age or older.
- Confirmed and documented diagnosis of HPV16-Positive oropharyngeal cancer.
- Comply with study procedures.
- Additional criteria may apply.